A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia.

Gunilla EnbladHannah KarlssonGustav GammelgårdJessica Wenthe Tanja Lövgren Rose-Marie AminiKristina I WikstromMagnus EssandBarbara SavoldoHelene HallböökMartin HöglundGianpietro DottiMalcolm K BrennerHans HagbergAngelica Loskog

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Third-generation CARs may be efficient in patients with advanced B-cell lymphoproliferative malignancy with only modest toxicity. Immune profiling pre- and posttreatment can be used to find response biomarkers.

Keyphrases

induced apoptosis
cell cycle arrest
epstein barr virus
diffuse large b cell lymphoma
oxidative stress
acute myeloid leukemia
study protocol
clinical trial
bone marrow
phase iii
single cell
phase ii
cancer therapy
endoplasmic reticulum stress
cell death
randomized controlled trial
signaling pathway
open label